The US FDA has granted breakthrough device designation to the company’s blood test, Elecsys pTau217 assay, for the diagnosis of Alzheimer’s disease
Developed in partnership with Eli Lilly, the assay is intended to detect the presence or absence of amyloid pathology in individuals enabling appropriate treatment through participation in clinical evaluations or accessing approved disease-modifying therapies
The Elecsys Phospho-Tau (217P) is an in vitro immunoassay developed for the determining Phospho-Tau (217P) protein quantitatively among individuals of age 60yrs. & above and is intended to diagnose Alzheimer’s disease
Ref: Roche | Image: Roche
Related News:- Roche’s Ventana HER2 (4B5) Test Receives CE Mark for HER2-Low Metastatic Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
